EMBioSys has developed a therapeutic non-pharmacological, electrode-free wearable garment called Efinia™ that delivers iEF Therapy (low intensity induced electric fields) to improve patient outcomes for treatment of breast cancer.  The market entry product will target triple-negative breast cancer (TNBC), which accounts for 40% of all breast cancer mortality.

iEF Therapy has the potential to inhibit cancer metastasis, shrink the primary tumor, improve efficacy of standard of care chemotherapy, and boost the natural immune response while selectively targeting only cancer cells.

This novel platform technology offers physicians a low risk, easily tolerated therapy to potentiate the standard of care for treatment of solid tumors, starting with breast cancer.

EMBioSys

Org chart

Teams

Offices